Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OC-001 in advanced solid tumors
NCT04260802Phase 2Terminated
- Sponsor
- Ocellaris Pharma, Inc.
- Start
- Sep 2020
- Primary completion
- Nov 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of OC-001 in triple-negative breast cancer (TNBC), gastric cancer (GC), Cervical Cancer (CC), ovarian cancer, hepatocellular carcinoma (HCC), sponsored by Ocellaris Pharma, Inc.. Started Sep 2020; status: terminated.
02
Drugs
OC-001
03
Conditions
triple-negative breast cancer (TNBC)gastric cancer (GC)Cervical Cancer (CC)ovarian cancerhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04260802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04260802.